Bilateral posterior subcapsular cataracts after inhaled budesonide therapy for bronchopulmonary dysplasia.

摘要

Introduction Inhaled corticosteroids (ICSs) have been used to treat or attempt to prevent CLD in the belief that topical treatment would be associated with fewer systemic adverse effects. An overview of trials of inhaled steroids concludes that although there are short-term beneficial effects with improved lung function and less need for later systemic steroids, there are no apparent long-term benefits and no effects on the mortality or risk of CLD [1]. Excessive doses and prolonged use of corticosteroids can impair head growth, neurodevelopmental outcome, lung structure and long-term survival. The use of systemic and/or ICSs is a risk factor for the development of posterior subcapsular cataracts (PSC) in adults. However, several studies have suggested that the use of ICSs does not increase the risk of cataracts in infants or children [1-3]. We report the development of bilateral posterior subcapsular cataracts in an infant treated with inhaled budesonide for bronchopulmonary dysplasia.